Skip to content

Author

Qingyuan Hu

We have 2 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

PROTAC probe-assisted degradomics identifies SPINT2 as a candidate cellular target involved in the anti-cancer activity of Flupentixol.

Targeted protein degradation has emerged not only as a therapeutic modality but also as a useful strategy for target deconvolution. This study investigated the anti-cancer activity and pharmacological targets of the anti-psychotic drug Flupentixol using a PROTAC probe-assisted degradomics strategy. We first verified th...

Ming-Yue Lv, Qing-Yuan Hu, Jing-Kai Liang et al. · 0 citations
Aug 2026

Discovery of DCAF16-based PROTACs as SHP2 degraders.

The design and synthesis of SHP2 PROTACs that recruit the DCAF16 E3 ligase for targeted SHP2 degradation are reported that support the potential of SHP2-targeted protein degradation as an alternative strategy to enzymatic inhibition and provide a promising starting point for the further development of SHP2 degraders.

X. Pang, Yuxin Gan, Qing-Yuan Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.